US stock · figures in US dollars · scored on full-year results
AbbVie AbbVie Inc. Common Stock
AbbVie scores 40/100 on fundamentals: in the bottom 16% of 503 scored S&P 500 stocks. Its strongest area is Business Strength (60/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.
- Carries a Weak Spot flag
An expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #50 of 60 in Healthcare by score
One-Minute Summary
Why AbbVie scores 40
An expensively priced stock, but price fairness needs attention.
Business Strength
60Why 60?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 18.5% over 4 years: customers keep spending more with this company.
Profit climbed about 29.8% over 4 years: the business keeps more money as it grows.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 17.5% over the last 8 quarters: customers keep spending more with this company.
The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.
Financial Safety
50Why 50?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 19.3% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
38Why 38?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 43.3% over the past year.
Risk
50Why 50?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
AbbVie (ABBV) scores 40/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 16% of 503 scored S&P 500 stocks.
Its strongest pillar is Business Strength (60/100); its weakest is Price Fairness (0/100).
AbbVie ranks #50 of 60 scored Healthcare stocks on Score Your Stock.
Yes. AbbVie (ABBV) has a dividend yield of 2.4%, from dividends with an ex-date in the last 12 months. It pays out 190% of its profit as dividends. Its Cash & Dividends pillar scores 38/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy ABBV. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
AbbVie (ABBV) is a Healthcare company (Drug Manufacturers - General). On Score Your Stock's fundamentals check, it scores 40/100, rated Okay. Its biggest strength is Business Strength (60/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 83 years of its current profit to buy (P/E 82.6×). It also pays back about 2.4% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/abbv-abbvie
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 64.4b | US$ 6.3b | US$ 19.5b | US$ 18.2b | US$ -1.3b | US$ 6.6b | US$ 70.8b | US$ 8.3b | US$ -5.9b | US$ 33.7b | US$ 41.6b | US$ 135.1b | US$ 141.0b | US$ 5.1b | - | -106% | 10% | -11.9× | 0.8× | 4.0× | 190% | - | - | - | - |
| 2025 | US$ 61.2b | US$ 4.2b | US$ 19.0b | US$ 17.8b | US$ -1.2b | US$ 5.2b | US$ 67.5b | US$ 8.6b | US$ -3.3b | US$ 29.1b | US$ 43.3b | US$ 134.0b | US$ 137.2b | US$ 5.0b | US$ 656.0m | -129% | 7% | -20.6× | 0.7× | 3.3× | 276% | 3% | 89.4× | -115.6× | - |
| 2024 | US$ 56.3b | US$ 4.3b | US$ 18.8b | US$ 17.8b | US$ -974.0m | US$ 5.5b | US$ 67.1b | US$ 6.8b | US$ 3.3b | US$ 25.6b | US$ 38.7b | US$ 135.2b | US$ 131.8b | US$ 4.2b | US$ 620.0m | 129% | 8% | 20.2× | 0.7× | 2.3× | 258% | 4% | 69.7× | 89.7× | - |
| 2023 | US$ 54.3b | US$ 4.9b | US$ 22.8b | US$ 22.1b | US$ -777.0m | US$ 12.8b | US$ 59.4b | US$ 7.2b | US$ 10.4b | US$ 33.0b | US$ 37.8b | US$ 134.7b | US$ 124.3b | US$ 4.1b | US$ 592.0m | 47% | 9% | 5.7× | 0.9× | 3.8× | 217% | 4% | 50.9× | 23.9× | 29.1 |